CD163 and seminoma: In contrast, our study includes a substantially larger cohort of patients with non-metastatic seminoma and, for the first time, provides a comprehensive quantitative and phenotypic analysis of TAMs (CD68+/CD163+), including their spatial distribution across pT1 and pT2 stages.